Cargando…

Virological and clinical rebounds of COVID-19 soon after nirmatrelvir/ritonavir discontinuation

Detalles Bibliográficos
Autores principales:	Antonelli, Guido, Focosi, Daniele, Turriziani, Ombretta, Tuccori, Marco, Brandi, Rossella, Fillo, Silvia, Ajassa, Camilla, Lista, Florigio, Mastroianni, Claudio M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250152/ https://www.ncbi.nlm.nih.gov/pubmed/35792281 http://dx.doi.org/10.1016/j.cmi.2022.06.029

Ejemplares similares

SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy
por: Edelstein, Gregory E., et al.
Publicado: (2023)

COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir
por: Epling, Brian P., et al.
Publicado: (2022)

Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19
por: Anderson, Annaliesa S., et al.
Publicado: (2022)

Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022)

Immunologic characterization of a patient with clinical and virologic rebound upon Nirmatrelvir/Ritonavir treatment: the unfortunate epilogue of COVID-19
por: Marchetti, Giulia, et al.
Publicado: (2023)

COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy
por: Coulson, J.M., et al.
Publicado: (2022)

Rebound of SARS-CoV-2 Infection after Nirmatrelvir–Ritonavir Treatment
por: Charness, Michael E., et al.
Publicado: (2022)

Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19
por: Birabaharan, Morgan, et al.
Publicado: (2022)

Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19
por: Zheng, Qian, et al.
Publicado: (2023)

Virologic and Immunologic Characterization of COVID-19 Recrudescence after Nirmatrelvir/Ritonavir Treatment
por: Carlin, Aaron F., et al.
Publicado: (2022)

Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022)

Nirmatrelvir and ritonavir for COVID-19
Publicado: (2022)

Clinical characteristics of COVID-19 rebound after nirmatrelvir-ritonavir or molnupiravir therapy: A prospective cohort study
por: Han, Jaijun, et al.
Publicado: (2023)

Does Nirmatrelvir/Ritonavir Influence the Immune Response against SARS-CoV-2, Independently from Rebound?
por: Panza, Francesca, et al.
Publicado: (2023)

Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)

Possible medication error risks with nirmatrelvir+ritonavir
Publicado: (2022)

Correction to: Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)

Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
por: Lu, Jiayue, et al.
Publicado: (2023)

Association nirmatrelvir/ritonavir contre la COVID-19
por: McDonald, Emily G., et al.
Publicado: (2022)

Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19
por: Reis, Stefanie, et al.
Publicado: (2022)

Benefits of nirmatrelvir–ritonavir remain unproven for some populations
por: McDonald, Emily G., et al.
Publicado: (2022)

Nirmatrelvir/ritonavir (Paxlovid®): French pharmacovigilance survey 2022
por: Bihan, Kevin, et al.
Publicado: (2023)

Real-world use of nirmatrelvir–ritonavir: who benefits?
por: Molina, Kyle C, et al.
Publicado: (2023)

Nirmatrelvir/ritonavir as a possible treatment for Long-COVID
por: Catalán, Ignacio Pérez, et al.
Publicado: (2023)

Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19
por: Reis, Stefanie, et al.
Publicado: (2023)

Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
por: Hung, Yuan-Pin, et al.
Publicado: (2022)

Generalized use of Nirmatrelvir plus ritonavir (Paxlovid): Raising concerns
por: Sánchez Fabra, David, et al.
Publicado: (2023)

Generalized use of Nirmatrelvir plus ritonavir (Paxlovid): Raising concerns
por: Sánchez Fabra, David, et al.
Publicado: (2023)

Inpatient remdesivir versus nirmatrelvir-ritonavir in the progression of COVID-19
por: Patel, Dimple, et al.
Publicado: (2023)

523. Efficacy and Safety of Nirmatrelvir/Ritonavir for COVID-19 in Adolescents
por: Lee, Kiriam Escobar, et al.
Publicado: (2023)

483. Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with Hemodialysis
por: Li, Xin, et al.
Publicado: (2023)

Best regimen for elexacaftor/ivacaftor/tezacaftor with nirmatrelvir-ritonavir for COVID-19?
Publicado: (2022)

Drug Interactions With Nirmatrelvir-Ritonavir in Older Adults Using Multiple Medications
por: Ross, Sydney B., et al.
Publicado: (2022)

VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19
por: Cao, Zhujun, et al.
Publicado: (2022)

Nirmatrelvir plus ritonavir in COVID-19: a profile of its use
por: Blair, Hannah A.
Publicado: (2022)

Tacrolimus Drug–Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin
por: Sindelar, Morganne, et al.
Publicado: (2022)

Ritonavir-boosted Nirmatrelvir and COVID-19 outcomes in the age of Omicron variant
por: Imran, Laiba, et al.
Publicado: (2023)

Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
por: Hashemian, Seyed Mohammad Reza, et al.
Publicado: (2023)

Can nirmatrelvir/ritonavir treatment shorten the duration of COVID-19 isolation?
por: Kim, Haein, et al.
Publicado: (2022)

Efficacy and safety of Nirmatrelvir/Ritonavir for treating the Omicron variant of COVID-19
por: Qiu, Chaochao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_86ec9eia0bkso6mvm028crlvs2